Hikma prepares to launch colchicine 0.6mg capsules in the US market

Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine 0.6mg capsules for the prophylaxis of gout flares in adults.



from The Medical News http://ift.tt/1xYu4hM